Invesco Ltd. Janux Therapeutics, Inc. Transaction History
Invesco Ltd.
- $516 Billion
- Q4 2024
A detailed history of Invesco Ltd. transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 284,662 shares of JANX stock, worth $8.28 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
284,662
Previous 9,938
2764.38%
Holding current value
$8.28 Million
Previous $451,000
3279.16%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding JANX
# of Institutions
228Shares Held
54.6MCall Options Held
687KPut Options Held
357K-
Ra Capital Management, L.P. Boston, MA10.4MShares$302 Million8.99% of portfolio
-
Janus Henderson Group PLC London, X03.56MShares$104 Million0.1% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.52MShares$102 Million7.18% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.06MShares$89.1 Million0.3% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$68.2 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.21B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...